Product Description
Mechanisms of Action: Sperm Degrader
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CONRAD
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Communicable Diseases|HIV Infections|Deficiency Diseases|Acquired Immunodeficiency Syndrome
Phase 2: Vaginitis|Inflammation|Mucositis
Phase 1: HIV Infections|Contraception
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A13-126 | P1 |
Completed |
Contraception |
2016-03-01 |
2019-03-20 |
Treatments |
|
| Biomarkers | P2 |
Completed |
Vaginitis|Inflammation|Mucositis |
2013-04-01 |
2019-03-19 |
Treatments |
|
| HIVNET 008 | P1 |
Completed |
HIV Infections |
None |
2019-03-21 |
Treatments |
|
| HIVNET 016 Pilot | P3 |
Completed |
Communicable Diseases|HIV Infections|Deficiency Diseases|Acquired Immunodeficiency Syndrome |
None |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|